What retatrutide is

• What retatrutide (LY3437943) is and why a single peptide hitting three receptors is a new idea
• How the GLP-1, GIP, and glucagon arms each contribute to appetite, glucose, and energy expenditure
• What the published phase 2 obesity, diabetes, and liver-fat trials actually showed, and what is still topline-only
• Where retatrutide sits in the regulatory and competitive landscape, and why investigational status matters

1. 01 What retatrutide is One peptide, three receptors, and the strongest weight-loss numbers yet free
2. 02 The molecule and its design Engineering one peptide to speak three hormonal languages paid
3. 03 The GLP-1 arm: appetite and glucose The appetite brake at the heart of the triple agonist paid
4. 04 The GIP arm: the second incretin The forgotten incretin that turned out to matter paid
5. 05 The glucagon arm: the differentiator The receptor that burns energy instead of just curbing intake paid
6. 06 Weight, glucose, and metabolic health What the phase 2 obesity and diabetes trials actually showed paid
7. 07 Liver, heart, and kidney effects Beyond the scale: what retatrutide does to organs paid
8. 08 Reading the clinical evidence How to grade what we actually know about retatrutide paid
9. 09 The obesity-drug landscape Where retatrutide fits in a crowded, fast-moving field paid
10. 10 Dosing & Administration How retatrutide is given in trials, and why dose escalation is everything paid
11. 11 Safety, side effects, and red flags What the safety data show, and the large gaps that remain paid
12. 12 Final exam Pass the final exam to earn your specialist certificate. Exam

For two decades, metabolic drugs hit one receptor. Then tirzepatide added a second. Retatrutide is the next step in that line: a single engineered peptide built to engage three receptors at once. Its arrival matters because the phase 2 weight-loss numbers are the largest yet reported for the class, which is exactly why this course works hard to separate that real signal from the hype around it.

Notice the shape of this story: a deep, fast-moving, well-funded program with published phase 2 wins, registrational obesity trials that have now reported, and a regulatory finish line still ahead. That is a very different evidence picture from an approved drug, and it is the throughline of every unit that follows.

The simplest way to picture retatrutide is one molecule reaching out to three different receptors, each contributing a different piece of the metabolic effect. Two of them, GIP and GLP-1, are incretin receptors that the body normally engages after a meal. The third, the glucagon receptor, is the unusual addition that aims to burn more energy rather than just eat less.

Pairing appetite suppression with a push on energy expenditure is the core idea. Eating less while also spending a little more energy is, in theory, a more powerful combination than either lever alone. Whether each arm contributes as cleanly in humans as the design intends is still being worked out, a caveat the mechanism units return to.

Before any results impress you, anchor on one fact: retatrutide is investigational. The registrational obesity trials have now finished and reported, and in July 2026 Lilly said it plans to submit retatrutide for US approval in the first quarter of 2027, once it completes the manufacturing package a biologics licence application needs. But the head-to-head against tirzepatide, the outcome trials, and much of the diabetes program are still running, and no regulator has cleared it for sale. Knowing exactly which rung of the ladder it stands on keeps every later number in proportion.

Retatrutide sits on the phase 3 rung, and much of that rung has now been climbed. The first peer-reviewed phase 3 readout, TRANSCEND-T2D-1 in type 2 diabetes, is published (Lancet, 2026), and the core obesity trials TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 have reported sponsor toplines. What is still genuinely future tense is the head-to-head against tirzepatide, the cardiovascular and kidney outcome trial, and any regulatory decision. That is an exciting place for a drug to be, and a place where responsible language matters most.

Here is the honest map of what retatrutide has and has not earned. The point of this course is to keep these tiers apart rather than rounding everything up to a finished, approved drug. Read the green and amber as real, and the red as genuinely open questions.

The gap between the green tiers and the red ones is the entire subject of this course. The phase 2 work is genuinely strong, and that is exactly why honest framing matters: a powerful early result is the easiest kind to over-sell as a finished, approved outcome.

Retatrutide is easiest to understand next to the drugs already on pharmacy shelves. Semaglutide hits one receptor, tirzepatide hits two, and retatrutide hits three. The pattern in the phase 3 numbers tracks that escalation, but so does the gap in evidence maturity, which runs the other way.

The trade is clear. Each added receptor tracks with a larger weight-loss signal, but retatrutide pays for its higher number with a thinner, earlier evidence base than the two approved drugs above it. The three figures also come from three different trials, each with its own population and its own statistical convention for handling people who stopped treatment, so treat them as three separate results rather than one clean ranking.

The figures that put retatrutide on the map come from its 48-week phase 2 obesity trial. They are worth seeing plainly, alongside the placebo group, because the gap between drug and placebo is what actually tells you the effect is real rather than the result of trial-wide lifestyle changes.

A roughly 24% average reduction against a 2% placebo response is a large, clean signal. The honest footnote is that 48 weeks is still the longest window in a peer-reviewed retatrutide obesity paper. Longer numbers now exist: 28.3% at 80 weeks on the top dose across everyone randomized in TRIUMPH-1 (on the efficacy estimand), and 30.3% at 104 weeks in a 532-person extension restricted to completers with a starting BMI of 35 or higher. Both are sponsor toplines whose full methods and safety tables have not been published yet.

A few specific claims you will meet online, held against the evidence tiers above. None is wildly false, but several round a real phase 2 finding up into a finished, approved certainty it has not earned. Reading each claim against its tier is the core skill this unit builds.

By the final exam you should be able to take any retatrutide marketing sentence and place it on this map yourself, tier by tier. That habit, not any single number, is what this course is really teaching.